论文部分内容阅读
目的:探讨玉屏风散联合脾氨肽治疗小儿反复呼吸道感染的临床疗效。方法:选取反复呼吸道感染患儿100例,随机分为对照组和治疗组各50例,对照组采用玉屏风散治疗,治疗组在对照组治疗的基础上加用脾氨肽治疗,比较观察两组的临床疗效。结果:治疗组的总有效率为96.0%,高于对照组的64.0%,差异有统计学意义(P<0.05);经过治疗后,治疗组1年内呼吸道感染急性发作的次数明显少于对照组(P<0.05)。结论:玉屏风散联合脾氨肽治疗小儿反复呼吸道感染疗效确切,可提高患儿的免疫力,值得临床推广应用。
Objective: To investigate the clinical efficacy of Yupingfengsan and spleen ammonia peptide in children with recurrent respiratory tract infections. Methods: 100 cases of children with recurrent respiratory tract infection were selected and randomly divided into control group and treatment group, 50 cases in each group. The control group was treated with Yupingfengsan. The treatment group was treated with splenic ammonia peptide on the basis of the control group. Group clinical efficacy. Results: The total effective rate of the treatment group was 96.0%, higher than 64.0% of the control group, the difference was statistically significant (P <0.05); after treatment, the number of acute attacks of respiratory tract infection in the treatment group was significantly less than that of the control group (P <0.05). Conclusion: Yupingfengsan combined with spleen ammonia peptide in children with recurrent respiratory tract infection curative effect is exact, can improve children’s immunity, worthy of clinical promotion and application.